HB3Y1G exhibits significant inhibitory activity against Streptococcus pneumoniae, a pathogenic bacterium associated with respiratory infections and pneumonia. It also shows moderate activity against Neisseria gonorrhoeae, the bacterium causing gonorrhea. This selective activity suggests potential application in the development of specific antimicrobial therapies.
The inhibitory activity demonstrated by HB3Y1G against these two pathogens is very promising and suggests its potential as a valuable therapeutic option in the development of new drugs. These results support the importance of research in the search for effective compounds against bacterial infections, especially in cases of strains resistant to existing treatments.
Know more about the pathogens